NHSA Releases 2026 NRDL Update Adding 107 Drugs Including Million‑Yuan CAR‑T Therapies – Ninth List Adjustment Since the Agency’s Establishment
China's National Healthcare Security Administration (NHSA) released the National Drug List for Basic Medical Insurance, Maternity Insurance, and Work‑Related Injury Insurance (NRDL) and the Commercial Health Insurance Innovative Drug List…
CHMP Backs Hansoh Pharma’s Aumolertinib – China’s First Homegrown Third‑Generation EGFR‑TKI Recommended for EU Approval in NSCLC
Hansoh Pharmaceutical Group (HKG: 3692) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of aumolertinib (overseas trade name: Aumseqa) for the treatment of…
Where biopharma's biggest deals take shape!
Betta Pharmaceuticals Licenses Next‑Generation ALK Inhibitor Ensartinib to Mankind Pharma for India – Upfront, Milestones and Tiered Royalties in Exclusive Territory Deal
Betta Pharmaceuticals (SHE: 300558) announced that it has entered into a licensing agreement with leading Indian pharmaceutical company Mankind Pharma (BOM: 543904; NSE: MANKIND), granting Mankind exclusive rights to ensartinib…
NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs
The Comprehensive Department of China's National Medical Products Administration (NMPA) has released the Measures for the Implementation of Drug Market Exclusivity (Draft for Comment), proposing a unified exclusivity regime that…
